Surgery pp 1699-1732 | Cite as

Benign and Malignant Diseases of the Breast

  • Helen A. Pass
Chapter

Abstract

Appreciation of the embryological development, anatomy, and physiology of the breast, is critical for the rational evaluation and treatment of benign, somatic breast complaints. Likewise, it is also a key factor in the appropriate selection and performance of surgical procedures, as well as the comprehensive, systematic application of adjuvant radiochemotherapy and surveillance of patients with breast cancer.

Keywords

Breast Cancer Sentinel Lymph Node Breast Cancer Risk Axillary Lymph Node Dissection Radical Mastectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tanner JM. Wachstun and Reining dis Menschen. Stuttgart, Germany: Georg Theime Verlag, 1962.Google Scholar
  2. 2.
    Henderson B, Ross R, Ludd H. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985; 56: 1206–1208.PubMedGoogle Scholar
  3. 3.
    MacMahon B, Cole P, Brown J. Etiology of human breast cancer: a review. J Natl Cancer Inst 1973; 50: 21–42.PubMedGoogle Scholar
  4. 4.
    MacMahon B, Trichopoulos D, Brown J. Age at menarche, probability of ovulation and breast cancer risk. Int J Cancer 1982; 29: 12–16.Google Scholar
  5. 5.
    Trichopoulos D, Yen S, Brown J. The effect of westernization on urine estrogens, frequency of ovulation, and breast cancer risk. Cancer 1984; 53: 187–192.PubMedGoogle Scholar
  6. 6.
    Thomas D, Lilienfeld A. Geographic, reproductive, and sociobiological factors. In: Stoll BA, ed. Risk Factors in Breast Cancer. Chicago: Heinemann, 1976: 25–53.Google Scholar
  7. 7.
    MacMahon B, Cole P, Lin T. Age at first birth and breast cancer risk. Bull World Health Organ 1970; 43: 209–221.PubMedGoogle Scholar
  8. 8.
    Trichopoulos D, Hsieh C, MacMahon B. Age at any birth and breast cancer risk. Int J Cancer 1983; 31: 701–704.PubMedGoogle Scholar
  9. 9.
    Brinton J, Hoover R, Fraumeni J. Reproductive factors in aetiology of breast cancer. Br J Cancer 1983; 47: 757–762.PubMedGoogle Scholar
  10. 10.
    Hadjimichael O, Boyle C, Meigs J. Abortion before first live birth and risk of breast cancer. Br J Cancer 1986; 53: 281–284.PubMedGoogle Scholar
  11. 11.
    Pike M, Henderson B, Casagrande J. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981; 43: 720–776.Google Scholar
  12. 12.
    Daling JR, Malone KE, Voigt LF, et al. Risk of breast cancer among young women: Relationship to induced abortion. J Natl Cancer Inst 1994; 86: 1584–1592.PubMedGoogle Scholar
  13. 13.
    Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med 1997; 336: 81–85.PubMedGoogle Scholar
  14. 14.
    Tavani A, LaVecchia C, Francheschi S, et al. Abortion and breast cancer risk. Int J Cancer 1996; 65: 401–405.PubMedGoogle Scholar
  15. 15.
    Henderson I. What can a woman do about her risk of dying of breast cancer? Curr Probl Cancer 1990; 14: 166–230.Google Scholar
  16. 16.
    Miller D, Rosenberg L, Kaufman D. Breast cancer before age 45 and oral contraceptive use: new findings. Am J Epidemiol 1989; 129: 269–280.PubMedGoogle Scholar
  17. 17.
    Bernstein L, Pike M, Krallo M, Henderson B. Update of the Los Angeles study of oral contraceptives and breast cancer. In: Mann R, ed. Oral Contraceptives and Breast Cancer. London: Parthenon Publishing Group, 1990: 169.Google Scholar
  18. 18.
    Meirik O, Lund E, Adami H Oral contraceptive use and breast cancer in young women. Lancet 1986; 2: 650–653.PubMedGoogle Scholar
  19. 19.
    McPherson K, Vessey M, Neil A. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987; 56: 653–660.PubMedGoogle Scholar
  20. 20.
    Carroll K. Experimental evidence of dietary factors and hormone dependent cancers. Cancer Res 1975; 35: 3374–3383.PubMedGoogle Scholar
  21. 21.
    Willett W, Stampfer M, Colditz G. Dietary fat and risk of breast cancer. N Engl J Med 1987; 316: 22–28.PubMedGoogle Scholar
  22. 22.
    Garfinkel L, Boffetta P, Stellman S. Alcohol and breast cancer: a cohort study. Prey Med 1988; 17: 686–693.Google Scholar
  23. 23.
    Longnecker P, Berlin J, Orz M. A metaanalysis of alcohol consumption in relation to breast cancer risk. JAMA 1988; 206: 652–656.Google Scholar
  24. 24.
    Harvey E, Schairer C, Brinton L. Alcohol consumption and breast cancer. J Natl Cancer Inst 1987; 78: 657–661.PubMedGoogle Scholar
  25. 25.
    Veer P, Kok F, Hermus R, Sturmans F. Alcohol dose, frequency, and age at first exposure in relation to the risk of breast cancer. Int J Epidemiol 1989; 18: 511–517.Google Scholar
  26. 26.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467.Google Scholar
  27. 27.
    Ottman R, King M, Pike M, Henderson B. Practical guide for estimating risk for familial breast cancer. Lancet 1983; 2: 556–558.PubMedGoogle Scholar
  28. 28.
    Anderson D. Genetic study of breast cancer: identification of a high risk group. Cancer 1974; 34: 1090–1097.PubMedGoogle Scholar
  29. 29.
    Anderson D, Badzioch M. Bilaterality in familial breast cancer patients. Cancer 1985; 56: 2092–2098.PubMedGoogle Scholar
  30. 30.
    Tokunaga M, Land C, Yamamoto T, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1980. Radiat Res 1987; 112: 243–272.PubMedGoogle Scholar
  31. 31.
    Miller A, Howe G, Sherman G. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 1989; 321: 1285–1289.PubMedGoogle Scholar
  32. 32.
    Shore R, Hildreth N. Breast cancer among women given x-ray therapy for acute postpartum mastitis. J Natl Cancer Inst 1986; 77: 689–696.PubMedGoogle Scholar
  33. 33.
    Hildreth N, Shore L, Dvoretsky P. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989; 321: 146–151.Google Scholar
  34. 34.
    Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146–151.PubMedGoogle Scholar
  35. 35.
    Gail M, Brinton L, Byar D, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–1886.PubMedGoogle Scholar
  36. 36.
    National Cancer Institute. http://cancertrials.nci.nih.gov/ 1998.Google Scholar
  37. 37.
    Lynch HT. Introduction to breast cancer genetics. In: Lynch HT, ed. Genetics and Breast Cancer. New York: Van Nostrand Reinhold, 1992: 1–13.Google Scholar
  38. 38.
    Miki Y, Swensen J, Shattuck-Eiden D, et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66.PubMedGoogle Scholar
  39. 39.
    Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–792.PubMedGoogle Scholar
  40. 40.
    Claus EB, Schildkraut J, Iversen ES Jr, et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 1998; 90: 1824–1829.PubMedGoogle Scholar
  41. 41.
    Brody LC, Biesecker BB. Breast cancer susceptibility genes: BRCA1 and BRCA2. Rev Mol Med 1998; 77: 208–226.Google Scholar
  42. 42.
    Narod SA, Reuteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17812-q23. Lancet 1991; 338: 82–83.PubMedGoogle Scholar
  43. 43.
    Akashi-Tanaka S, Fukutomi T, Tukami A, et al. Male breast cancer in patients with a familial history of breast cancer. Surg Today 1996; 26: 975–979.PubMedGoogle Scholar
  44. 44.
    Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994; 7: 103–107.PubMedGoogle Scholar
  45. 45.
    Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P1 study. J Natl Cancer Inst 1998; 90: 1371–1388.PubMedGoogle Scholar
  46. 46.
    Fisher B, Costantino JP, Redmond C, et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989; 320: 479–484.PubMedGoogle Scholar
  47. 47.
    Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without Tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986; 4: 459–471.PubMedGoogle Scholar
  48. 48.
    Mouridsen H, Palshof T, Patterson J, et al. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978; 5: 137–141.Google Scholar
  49. 49.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with Tamoxifen: preliminary findings from the Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–97.PubMedGoogle Scholar
  50. 50.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98101.Google Scholar
  51. 51.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77–84.PubMedGoogle Scholar
  52. 52.
    Adair FE. Clinical manifestations of early cancer of the breast-with a discussion on the subject of biopsy. N Engl J Med 1933; 208: 1250–1255.Google Scholar
  53. 53.
    Foster RS, Costanza MC. Breast self examination practices and breast cancer survival. Cancer 1984; 53: 999.PubMedGoogle Scholar
  54. 54.
    Semiglazar VF, Moiseyenko VM, Bauli JL, et al. The role of breast self-examination in early breast cancer detection (results of the 5 year USSR/WHO randomized study in Leningrad). Eur J Epidemiol 1992; 8: 498.Google Scholar
  55. 55.
    Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst 1997; 89: 355–365.PubMedGoogle Scholar
  56. 56.
    Boyd NF, Sutherland HF, Fish EB, et al. Prospective evaluation of physical examination of the breast. Am J Surg 1981; 142: 331.PubMedGoogle Scholar
  57. 57.
    Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study 2: breast cancer detection and death rates among women 50 to 59 years. Can Med Assoc J 1992; 147: 1477.Google Scholar
  58. 58.
    Ciatto J, Catalion L, Distante V. Nonpalpable breast lesions detected with mammography: review of 512 consecutive cases. Radiology 1987; 165: 99–102.PubMedGoogle Scholar
  59. 59.
    Sox HC Jr. Preventive health services in adults. N Engl J Med 1993; 330: 1589.Google Scholar
  60. 60.
    Fletcher S, Black W, Harris R, et al. Special article: report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993; 85: 1644.PubMedGoogle Scholar
  61. 61.
    National Institutes of Health. Breast cancer screening for women ages 40–49. NIH Consensus Statement 1997, 45: 1–35.Google Scholar
  62. 62.
    Morrow M. Surgery in the elderly patient, I: breast disease in elderly women. Surg Clin North Am 1994; 74: 145.PubMedGoogle Scholar
  63. 63.
    Coleman EA, Feuer EJ, NCI Breast Cancer Screening Consortium Members. Breast cancer screening among women from 65 to 74 years of age in 1987–88 and 1991. Ann Intern Med 1992, 417: 961.Google Scholar
  64. 64.
    Rimer BK, Ross E, Cristinzio S. Older women’s participation in breast screening. J Gerontol 1992; 47: 85.PubMedGoogle Scholar
  65. 65.
    Wilson TE, Helvie MA, August DA. Breast imaging: breast cancer in elderly patients, early detection with mammography. Radiology 1994; 190: 203.PubMedGoogle Scholar
  66. 66.
    American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). Reston, VA: American College of Radiology, 1993.Google Scholar
  67. 67.
    Schmidt RA. Stereotactic breast biopsy. CA Cancer J Clin 1994; 44: 172–191.Google Scholar
  68. 68.
    Al-Sobhi S, Helvie MA, Pass HA, Chang AE. Extent of lumpectomy for breast cancer after diagnosis by stereotactic core versus wire localization biopsy. Ann Surg Oncol (in press).Google Scholar
  69. 69.
    Dronkers DJ. Stereotaxic core biopsy of breast lesions. Radiology 1992; 183: 631–634.PubMedGoogle Scholar
  70. 70.
    Parker SH, Lovin JD, Jobe WE, et al. Nonpalpable breast lesions: stereotactic automated large-core biopsies. Radiology 1991; 180: 403–407.PubMedGoogle Scholar
  71. 71.
    Jackman RJ, Nowels KW, Shepard MJ, et al. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 1994; 193: 91–95.PubMedGoogle Scholar
  72. 72.
    Liberman L, Cohen MA, Dershaw DD, et al. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. Am J Roentgenol 1995; 164: 1111–1113.Google Scholar
  73. 73.
    Jackman RJ, Finkelstein SI, Marzoni FA. Stereotaxic large-core needle biopsy of histologically benign, nonpalpable breast lesions: false-negative results and failed follow up. Radiology 1995; 193: 91–95.Google Scholar
  74. 74.
    Parker S, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology 1994; 193: 359–364.PubMedGoogle Scholar
  75. 75.
    Food and Drug Administration Medical Devices, Diagnostics, and Instrumentation (“The Grey Sheet”). http://www fda gov/cdrh/ost/appendix_h html 1998; accessed June 30, 1998.Google Scholar
  76. 76.
    Smith BL, Souba WW. Algorithm and explanation: assessment and management of breast complaints. Common Clin Prob 1995: 1–17.Google Scholar
  77. 77.
    Pashby NL, Mansel RE, Hughes LE, et al. A clinical trial of evening primrose oil in mastalgia. Br J Surg 1981; 68: 801.Google Scholar
  78. 78.
    Baker H, Snedecor P. Clinical trial of danazol for benign breast disease. Am Surg 1979; 45: 727.PubMedGoogle Scholar
  79. 79.
    Lauersen N, Wilson K. The effect of danazol in the treatment of chronic mastitis. Obstet Gynecol 1976; 48: 93.PubMedGoogle Scholar
  80. 80.
    Mansel R, Preece P, Hughes L. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 1978; 65: 724.PubMedGoogle Scholar
  81. 81.
    Devitt JE. Management of nipple discharge by clinical findings. Am J Surg 1985; 149: 789.PubMedGoogle Scholar
  82. 82.
    Leis HP Jr, Greene FL, Cammarata A, et al. Nipple discharge: surgical significance. South Med J 1988; 81: 20.PubMedGoogle Scholar
  83. 83.
    Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill-Livingstone, 1987.Google Scholar
  84. 84.
    Dixon JM, Dobie V, Laub J, et al. Assessment of the acceptability of conservative management of fibroadenoma of the breast. Br J Surg 1996; 83: 264–265.Google Scholar
  85. 85.
    Cooper JS, Henson DE, et al. In: Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997: 171–178.Google Scholar
  86. 86.
    Van Lancker M, Goor C, Sacre R, et al. Patterns of axillary lymph node metastasis in breast cancer. Am J Clin Oncol 1995; 18: 267–272.PubMedGoogle Scholar
  87. 87.
    Frykberg ER, Bland KI. Management of in situ and minimally invasive breast carcinoma. World J Surg 1994; 18: 45.PubMedGoogle Scholar
  88. 88.
    Page DL, Dupont W, Rogers L, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 1982; 49: 751–758.PubMedGoogle Scholar
  89. 89.
    Rosen P, Brown D, Kinne D. The clinical significance of pre-invasive breast carcinoma. Cancer 1980; 46: 919–925.PubMedGoogle Scholar
  90. 90.
    Fisher B, Costantino JP, Redmond C, et al. Lumpectomy corn-pared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 1581–1586.PubMedGoogle Scholar
  91. 91.
    Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42: 737–769.PubMedGoogle Scholar
  92. 92.
    Alpers C, Wellings S. The prevalence of carcinoma in situ in normal and cancer-associated breast. Hum Pathol 1985; 16: 796–807.PubMedGoogle Scholar
  93. 93.
    Bartow S, Pathak D, Black W, Key C, Teaf S. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. Cancer 1987; 60: 2751–2760.PubMedGoogle Scholar
  94. 94.
    Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky B. Radiation therapy for intraductal carcinoma: is it an equal alternative? Arch Surg 1991; 126: 424–427.PubMedGoogle Scholar
  95. 95.
    Kinne D, Petrek J, Osborne M, Fracchia A, De Palo A, Rosen PP. Breast carcinoma in situ. Arch Surg 1989; 124: 33–36.PubMedGoogle Scholar
  96. 96.
    Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for Tla breast carcinoma: is it indicated? Cancer 1994; 73: 664–667.PubMedGoogle Scholar
  97. 97.
    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441–452.PubMedGoogle Scholar
  98. 98.
    Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected duct carcinoma in situ: frequency of local recur-rente following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63: 618.PubMedGoogle Scholar
  99. 99.
    Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818–1822.PubMedGoogle Scholar
  100. 100.
    Wolmark N, Dignam J, Fisher B. The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): Preliminary results of NSABP protocol B24 [abstract]. Br Cancer Res Treat 1998; 50: 227.Google Scholar
  101. 101.
    Ashikari R, Hajdu SI, Robbins GF. Intraductal carcinoma of the breast (1960–1969). Cancer 1971; 28: 1182.PubMedGoogle Scholar
  102. 102.
    Weber BL, Heise H, Neifield JP, et al. Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carcinoma. Cancer 1981; 47: 2928.Google Scholar
  103. 103.
    Schwartz G, Feig S, Rosenberg A. Staging and treatment of clinically occult breast cancer. Cancer 1984; 53: 1379.PubMedGoogle Scholar
  104. 104.
    Wheeler J, Enterline H, Rosenman J. Lobular carcinoma in situ of the breast. Long-term follow-up. Cancer 1974; 34: 554–563.PubMedGoogle Scholar
  105. 105.
    Frykberg E, Santiago F, Betsill W, O’Brien P. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet 1987; 164: 285–301.PubMedGoogle Scholar
  106. 106.
    McDivitt R, Hutter R, Foote F, Stewart F. In situ lobular carcinoma. A prospective follow up study indicating cumulative patient risks. JAMA 1967; 201: 82–86.PubMedGoogle Scholar
  107. 107.
    Rosen P, Lieberman P, Braun D. Lobular carcinoma in situ of the breast. Am J Surg 1978; 2: 225–251.Google Scholar
  108. 108.
    Page DL, Jensen RA. Evaluation and management of high risk and premalignant lesions of the breast. World J Surg 1994; 18: 32.PubMedGoogle Scholar
  109. 109.
    Rosen PP, Kosloff C, Lieberman P, et al. Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am J Pathol 1978; 2: 225.Google Scholar
  110. 110.
    Fisher ER, Fisher B. Lobular carcinoma of the breast: an overview. Ann Surg 1977; 185: 377.PubMedGoogle Scholar
  111. 111.
    Broca PP. Traite des tumeurs. Paris: Asselin, 1866.Google Scholar
  112. 112.
    Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH. Tumor variation in families with breast cancer. JAMA 1972; 222: 1631–1635.PubMedGoogle Scholar
  113. 113.
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265–271.PubMedGoogle Scholar
  114. 114.
    Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage [see comments]. Cancer 1996; 77: 697–709.PubMedGoogle Scholar
  115. 115.
    Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994; 7: 103–107.PubMedGoogle Scholar
  116. 116.
    Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747–752.PubMedGoogle Scholar
  117. 117.
    Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992; 52: 2984–2986.PubMedGoogle Scholar
  118. 118.
    Brownstein MH, Wolf M, Bikowski JB. Cowden’s disease: a cutaneous marker of breast cancer. Cancer 1978; 41: 2393–2398.PubMedGoogle Scholar
  119. 119.
    Williard W, Borgen P, Bol R, Tiwari R, Osborne M. Cowden’s disease: a case report with analyses at the molecular level. Cancer 1992; 69: 2969–2974.PubMedGoogle Scholar
  120. 120.
    Gatti RA, Berkel I, Boder E, et al. Localization of an ataxiatelangiectasia gene to chromosome 11g22–23. Nature 1988; 336: 577–580.PubMedGoogle Scholar
  121. 121.
    Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxiatelangiectasia in the United States. Am J Hum Genet 1986; 39: 573–583.PubMedGoogle Scholar
  122. 122.
    Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185–187.PubMedGoogle Scholar
  123. 123.
    Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57: 1–7.PubMedGoogle Scholar
  124. 124.
    Halsted W. The results of operations cure of cancer of the breast performed at Johns Hopkins Hospital. Johns Hopkins Hosp Bull 1894; 4: 497–555.Google Scholar
  125. 125.
    Adair FE, Berg J, Joubert L, Robbins GF. Long-term follow-up of breast cancer patients: the 30-year report. Cancer 1974; 33: 1145–1150.PubMedGoogle Scholar
  126. 126.
    Haagensen CD, Bodian C. A personal experience with Halsted’s radical mastectomy. Ann Surg 1984; 199: 143–150.PubMedGoogle Scholar
  127. 127.
    Say C, Donegan WL. A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet 1974; 138: 370–376.PubMedGoogle Scholar
  128. 128.
    Forrest A, Roberts M, Cant E. Simple mastectomy and pectoral node biopsy: the Cardiff-St. Mary’s Trial. World J Surg 1977; 1: 320–323.PubMedGoogle Scholar
  129. 129.
    Urban JA. Management of operable breast cancer: the surgeon’s view. Cancer 1978; 42: 2066–2077.PubMedGoogle Scholar
  130. 130.
    Veronesi U, Valagussa P. Inefficacy of internal mammary node dissection in breast cancer surgery. Cancer 1981; 47: 170–175.PubMedGoogle Scholar
  131. 131.
    Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 1978; 41: 10.Google Scholar
  132. 132.
    Haagensen CD. Diseases of the Breast. 3rd ed. Philadelphia: WB Saunders, 1986.Google Scholar
  133. 133.
    Robinson G, Van Heerden J, Payne WEA. The primary surgical treatment of carcinoma of the breast: a changing trend toward modified radical mastectomy. Mayo Clin Proc 1976; 51: 433–442.PubMedGoogle Scholar
  134. 134.
    Baker R, Montague A, Childs J. A comparison of modified radical mastectomy to radical mastectomy in the treatment of operable breast cancer. Ann Surg 1979; 189: 553–559.PubMedGoogle Scholar
  135. 135.
    Turner L, Swindell R, Bell W. Radical versus modified radical mastectomy for breast cancer. Ann R Coll Surg Engl 1981; 63: 239–243.PubMedGoogle Scholar
  136. 136.
    Maddox W, Carpenter J, Laws H. A randomized prospective trial of radical mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 1983; 198: 207–212.PubMedGoogle Scholar
  137. 137.
    Maddox W, Carpenter J, Laws H, et al. Does radical mastectomy still have a place in the treatment of primary operable breast cancer? Arch Surg 1987; 122: 1320.Google Scholar
  138. 138.
    Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305: 6.PubMedGoogle Scholar
  139. 139.
    Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized clinical trial. Eur J Cancer 1990; 26: 668.PubMedGoogle Scholar
  140. 140.
    Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822.PubMedGoogle Scholar
  141. 141.
    Lagios MD, Westdahl PR, Rose M. The concept and implications of multicentricity in breast carcinoma. Pathol Annu 1981; 16: 83–102.PubMedGoogle Scholar
  142. 142.
    Holland R, Velig S, Mravunac M, Hendricks J. Histologic multifocality of Tis, T1–2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer 1985; 56: 979–990.PubMedGoogle Scholar
  143. 143.
    Harris r, Recht A. Conservative surgery and radiotherapy. In: Harris J, Hellman S, Henderson IC, Kinne D, eds. Breast Diseases. Philadelphia: JB Lippincott, 1991: 399–404.Google Scholar
  144. 144.
    Vicini F, Eberlein T, Connolly J, et al. The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy. Ann Surg 1991; 214: 200–205.PubMedGoogle Scholar
  145. 145.
    Kurtz J, Jacquemier J, Amalric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990; 8: 591–598.PubMedGoogle Scholar
  146. 146.
    NIH Consensus Development Conference Treatment of early-stage breast cancer. NIH Consens Statement 1990; 8: 1–19.Google Scholar
  147. 147.
    Fisher B, Montague A, Redmond C, et al. Comparison of radical mastectomy with alternatives for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer 1977; 39: 2827.PubMedGoogle Scholar
  148. 148.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674.PubMedGoogle Scholar
  149. 149.
    Moffat FL Jr, Senofsky GM, Davis K, Clark KC, Robinson DS, Ketcham AS. Axillary node dissection for early breast cancer: some is good, but all is better. J Surg Oncol 1992; 51: 8–13.PubMedGoogle Scholar
  150. 150.
    NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 391–395.Google Scholar
  151. 151.
    Schottenfeld D, Nash AG, Robbins GF, Beattie EJ Jr. Ten-year results of the treatment of primary operable breast carcinoma: a summary of 304 patients evaluated by the TNM system. Cancer 1976; 38: 1001–1007.PubMedGoogle Scholar
  152. 152.
    Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 1978; 41: 1170–1178.PubMedGoogle Scholar
  153. 153.
    Haagensen CD. Treatment of curable carcinoma of the breast. Int J Radiat Oncol Biol Phys 1977; 2: 975–980.PubMedGoogle Scholar
  154. 154.
    Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975; 140: 528–534.PubMedGoogle Scholar
  155. 155.
    Payne WS, Taylor WF, Khonsari S, et al. Surgical treatment of breast cancer: trends and factors affecting survival. Arch Surg 1970; 101: 105–113.PubMedGoogle Scholar
  156. 156.
    Ferguson DJ, Meier P, Karrison T, Dawson PJ, Straus FH, Lowenstein FE. Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA 1982; 248: 1337–1341.PubMedGoogle Scholar
  157. 157.
    Smith JA III, Gamez-Araujo JJ, Gallager HS, White EC, McBride CM. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer 1977; 39: 527–532.PubMedGoogle Scholar
  158. 158.
    Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992; 66: 136–138.PubMedGoogle Scholar
  159. 159.
    Tasmuth T, von Smitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer 1996; 74: 2024–2031.PubMedGoogle Scholar
  160. 160.
    Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11: 1536–1544.PubMedGoogle Scholar
  161. 161.
    Hladiuk M, Huchcroft S, Temple W, et al. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Orcol 1992; 50: 47–52.Google Scholar
  162. 162.
    Keramopoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology 1993; 50: 445–449.PubMedGoogle Scholar
  163. 163.
    Britton RC, Nelson PA. Cause and treatment of postmastectomy lymphedema of the arm: report of 114 cases. JAMA 1962; 180: 95102.Google Scholar
  164. 164.
    Dewar JA, Sarrazin D, Benhamou E, et al. Management of the axilla in conservatively treated breast cancer: 592 patients treated at Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys 1987; 13: 475–481.PubMedGoogle Scholar
  165. 165.
    Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intra-ductal breast cancer. Arch Surg 1990; 125: 1298–1301.PubMedGoogle Scholar
  166. 166.
    McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast: clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982; 6: 401–411.PubMedGoogle Scholar
  167. 167.
    Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391–401.PubMedGoogle Scholar
  168. 168.
    Turner RR, Ollina DW, Krasne DL, Giuliano AE. Histopatho-logic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997; 226: 271–276.PubMedGoogle Scholar
  169. 169.
    Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International [Ludwig[Breast Cancer Study Group [see comments]. Lancet 1990; 335: 1565–1568.Google Scholar
  170. 170.
    Trojani M, de M I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55: 303–306.PubMedGoogle Scholar
  171. 171.
    Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction: comparison between MUC1 and mRNA and keratin 19 mRNA amplification. Am J Pathol 1996; 148: 649–656.PubMedGoogle Scholar
  172. 172.
    Danforth DN. The role of axillary lymph node dissection in the management of breast cancer. In: Rosenberg S, Devita V, Hellman S, eds. Principles and Practice of Oncology Updates. Vol. 6. Philadelphia: Lippincott-Raven 1992: 1–16.Google Scholar
  173. 173.
    Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1NOMO/T2NOMO patients with long-term follow-up. J Clin Oncol 1993; 11: 2090–2100.PubMedGoogle Scholar
  174. 174.
    Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473–478.PubMedGoogle Scholar
  175. 175.
    Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil [see comments]. J Clin Oncol 1996; 14: 1982–1992.PubMedGoogle Scholar
  176. 176.
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479–484.PubMedGoogle Scholar
  177. 177.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments]. J Natl Cancer Inst 1996; 88: 1529–1542.PubMedGoogle Scholar
  178. 178.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women [see comments]. Lancet 1992; 339: 71–85.Google Scholar
  179. 179.
    Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10: 387–395.PubMedGoogle Scholar
  180. 180.
    Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer [see comments]. N Engl J Med 1996; 334: 1356–1361.PubMedGoogle Scholar
  181. 181.
    Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483–1496.PubMedGoogle Scholar
  182. 182.
    Bedwinek JM, Lee J, Fineberg B, Ocwieza M. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 1981; 47: 2232–2235.PubMedGoogle Scholar
  183. 183.
    Stefanik D, Goldberg R, Byrne P, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1985; 3: 660–665.PubMedGoogle Scholar
  184. 184.
    Jones JM, Ribeiro GG. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy [see comments]. Clin Radiol 1989; 40: 204–208.PubMedGoogle Scholar
  185. 185.
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial [see comments]. N Engl J Med 1997; 337: 949–955.PubMedGoogle Scholar
  186. 186.
    Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [see comments]. N Engl J Med 1997; 337: 956–962.PubMedGoogle Scholar
  187. 187.
    Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res 1987; 47: 3889–3894.PubMedGoogle Scholar
  188. 188.
    Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19: 278–285.PubMedGoogle Scholar
  189. 189.
    Hortobagyi GN, Ames FC, Buzdar AU, et al. Managements of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507–2516.PubMedGoogle Scholar
  190. 190.
    Hobar PC, Jones RC, Schouten J, Leitch AM, Hendler F. Multi-modality treatment of locally advanced breast carcinoma. Arch Surg 1988; 123: 951–955.PubMedGoogle Scholar
  191. 191.
    Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988; 6: 261–269.PubMedGoogle Scholar
  192. 192.
    Lippman ME, Sorace RA, Bagley CS, Danforth DW Jr, Lichter A, Wesley MN. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. Monogr Natl Cancer Inst 1986: 1: 153–159.Google Scholar
  193. 193.
    Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4: 1765–1771.PubMedGoogle Scholar
  194. 194.
    Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast, II: Inflammatory carcinoma. Cancer 1994; 74 (suppl 1]: 466–476.PubMedGoogle Scholar
  195. 195.
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: protocol 19 Aredia Breast Cancer Study Group [see comments] N Engl J Med 1996; 335: 1785–1791.Google Scholar
  196. 196.
    Paget J. Disease of the mammary areola preceding cancer of the mammary gland. St Bart Hosp Rep 1874; 10: 79–89.Google Scholar
  197. 197.
    Pierce LJ, Haffty BG, Sohn LJ, et al. The conservative management of Paget’s disease of the breast with radiotherapy. Cancer 1997; 80: 1065–1072.PubMedGoogle Scholar
  198. 198.
    Harris J, Morrow M, Bonadonna G. Cancer of the breast. In: Harris J, Lippman M, Morrow M, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996: 129.Google Scholar
  199. 199.
    Campana F, Forquet A, Ashby M. Presentation of axillary lymphadenopathy without detectable breast primary: experience at Institut Curie. Radiol Oncol 1989; 15: 321–325.Google Scholar
  200. 200.
    Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases: updated management. Arch Surg 1990; 125: 210–214.PubMedGoogle Scholar
  201. 201.
    Karlsson P, Holmberg E, Johansson KA, Kindblom LG, Carstensen J, Wallgren A. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996; 38: 25–31.PubMedGoogle Scholar
  202. 202.
    American Cancer Society. Guidelines for the cancer related checkup. http://www.cancer.org/guide/guidchec.html 1997.
  203. 203.
    National Cancer Institute. Breast cancer screening. In: PDQ: detection and prevention. http://cancernet.nci.nih.gov/clinpdq/ screening/Screening_for_breast_cancer_Physician.html 1997.
  204. 204.
    National Cancer Advisory Board. National cancer advisory board mammography recommendations for women ages 40–49. http://cancernet.nci.nih.gov/news/ncabrec.html 1997.
  205. 205.
    American College of Radiology. ACR standard for the perfor-mance of screening mammography. http://www.acr.org/departments/stand_accred/standards/pdf_standards/toc.pdf 1997.
  206. 206.
    American College of Obstetricians and Gynecologists. ACOG news release: April 1997 press statement on mammography screening guidelines. http://www.acog.org/from_home/publications/press_releases/nr-mammos.html 1997.
  207. 207.
    American Academy of Family Physicians. AAFP recommendations for periodic health examination. In: 1996–1997 AAFP Reference Manual: Clinical Policies. http://www.aafp.org/family/policy/camp/14.html 1997.
  208. 208.
    US Preventive Services Task Force. Highlights: US Preventive Services Task Force Guide to Clinical Preventive Services. 2nd ed. http://www.ahcpr.gov/clinic/uspstf.html 1997.
  209. 209.
    Shapiro S, Venet W, Strax P, et al. Current results of the breast cancer screening randomized trial: the Health Insurance Plan [HIP] of Greater New York study. In: Screening for Breast Cancer. Toronto: Sam Huber Publishing, 1988.Google Scholar
  210. 210.
    Morrison A, Brisson J, Khalid N. Breast cancer incidence and mortality in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988; 80: 1540.PubMedGoogle Scholar
  211. 211.
    Hurley SF, Kaldor JM. The benefits and risks of mammographie screening for breast cancer. Epidemiol Rev 1992; 14: 101.PubMedGoogle Scholar
  212. 212.
    Alexander FE, Anderson TJ, Brown HK, et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer 1994; 70: 542.PubMedGoogle Scholar
  213. 213.
    Andersson I, Aspegren K, Janzon L, et al. Mammographie screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 297: 943.PubMedGoogle Scholar
  214. 214.
    Tabar L, Faberberg G, Duffy S, et al. Breast imaging: current status and future directions: update of the Swedish Two-County Program of mammographie screening for breast cancer. Radio! Clin North Am 1992; 30: 187.PubMedGoogle Scholar
  215. 215.
    Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study, 1: breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 1992; 147: 1458.Google Scholar
  216. 216.
    Bjurstam N, Björneld L, Duffy SW, et al. The Gothenburg breast screening trial. Cancer 1997; 80: 2091–2099.PubMedGoogle Scholar
  217. 217.
    Ohuchi N, Yoshida K, Kimura M, et al. Improved detection rate of early breast cancer in mass screening combined with mammography. Jpn J Cancer Res 1993; 84: 807.PubMedGoogle Scholar
  218. 218.
    Hayward J. The Guy’s trials on “early” breast cancer. World J Surg 1977; 1: 314.PubMedGoogle Scholar
  219. 219.
    Sarrazin D, Le M, Arriagada R, et al. Ten-year results of a ran-domized trial comparing a conservative treatment to mastec-tomy in early breast cancer. Radiother Oncol 1989; 14: 177.PubMedGoogle Scholar
  220. 220.
    Lichter A, Lippman M, Danforth D, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol 1992; 10: 976.PubMedGoogle Scholar
  221. 221.
    Van Dongen J, Bartelink H, Fentimen I, et al. Randomized clinical trial to assess the value of breast conserving therapy in Stage I and II breast cancer: EORTC 10801 trial. Monogr J Natl Cancer Inst 1992; 11: 15.Google Scholar
  222. 222.
    Blichert-Toft M, Rose C, Andersen J, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Monogr J Natl Cancer Inst 1992; 11: 19.Google Scholar
  223. 223.
    Krag D, Harlow S, Weaver D, Ashikaga T. Technique of sentinel node resection in melanoma and breast cancer: probe-guided surgery and lymphatic mapping. Eur J Surg Oncol 1998; 24: 89–93.PubMedGoogle Scholar
  224. 224.
    Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335–339.PubMedGoogle Scholar
  225. 225.
    Borgstcin PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer [letter] [see comments]. Lancet 1997; 349: 1668–1669.Google Scholar
  226. 226.
    Giuliano AE. Intradermal blue dye to identify sentinel lymph node in breast cancer [letter; comment]. Lancet 1997; 350: 958.PubMedGoogle Scholar
  227. 227.
    Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997; 3: 336–340.PubMedGoogle Scholar
  228. 228.
    Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864–1867.PubMedGoogle Scholar
  229. 229.
    Barnwell JM, Arredondo MA, Kollmorgen D, et al. Sentinel node biopsy in breast cancer. Ann Surg One 1998; 126–130.Google Scholar
  230. 230.
    Borgstein PJ, Pijpers R, Comans EF, Van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186: 275–283.PubMedGoogle Scholar
  231. 231.
    Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study [see comments]. N Engl J Med 1998; 339: 941–946.PubMedGoogle Scholar
  232. 232.
    O’Hea BJ, Hill ADK, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998; 186: 423–427.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Helen A. Pass

There are no affiliations available

Personalised recommendations